Histology-driven chemotherapy of soft-tissue sarcoma.
(2010) In Annals of Oncology 21. p.270-276- Abstract
- Soft-tissue sarcomas are rare diseases with >50 subtypes. Surgery is the most important treatment in localized disease, sometimes combined with radiotherapy. Chemotherapy is used as palliation in advanced disease, sometimes also with a potential to decrease tumour size and eradicate micro-metastases, making meaningful surgery possible. The role of chemotherapy as adjuvant treatment in localized disease is not finally settled. Doxorubicin and ifosfamide are the two drugs with the best established response rates in soft-tissue sarcoma, and a combination of these drugs has been a 'gold standard' for several years. However, there is an emerging knowledge of the biology and sensitivity to treatment for different histological subtypes. New... (More)
- Soft-tissue sarcomas are rare diseases with >50 subtypes. Surgery is the most important treatment in localized disease, sometimes combined with radiotherapy. Chemotherapy is used as palliation in advanced disease, sometimes also with a potential to decrease tumour size and eradicate micro-metastases, making meaningful surgery possible. The role of chemotherapy as adjuvant treatment in localized disease is not finally settled. Doxorubicin and ifosfamide are the two drugs with the best established response rates in soft-tissue sarcoma, and a combination of these drugs has been a 'gold standard' for several years. However, there is an emerging knowledge of the biology and sensitivity to treatment for different histological subtypes. New drugs such as gemcitabine, taxanes and trabectedin have been explored in several studies, showing promising results. Even if most studies have encompassed many different subtypes and were limited in size, knowledge related to specific treatment for different subtypes is emerging. Examples are trabectedin in liposacoma and leiomyosarcoma, and taxanes in angiosarcoma. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1711211
- author
- Eriksson, Mikael LU
- organization
- publishing date
- 2010
- type
- Chapter in Book/Report/Conference proceeding
- publication status
- published
- subject
- host publication
- Educational Book of the 35th ESMO Congress Milan, Italy, 8-12 October 2010
- series title
- Annals of Oncology
- volume
- 21
- edition
- Suppl 7
- pages
- 270 - 276
- external identifiers
-
- wos:000283099200038
- pmid:20943627
- scopus:78649391724
- ISSN
- 1569-8041
- DOI
- 10.1093/annonc/mdq285
- language
- English
- LU publication?
- yes
- id
- 2d279b0c-d4fc-4e77-b60f-9372ead13751 (old id 1711211)
- date added to LUP
- 2016-04-04 09:29:06
- date last changed
- 2022-02-16 02:58:59
@inproceedings{2d279b0c-d4fc-4e77-b60f-9372ead13751, abstract = {{Soft-tissue sarcomas are rare diseases with >50 subtypes. Surgery is the most important treatment in localized disease, sometimes combined with radiotherapy. Chemotherapy is used as palliation in advanced disease, sometimes also with a potential to decrease tumour size and eradicate micro-metastases, making meaningful surgery possible. The role of chemotherapy as adjuvant treatment in localized disease is not finally settled. Doxorubicin and ifosfamide are the two drugs with the best established response rates in soft-tissue sarcoma, and a combination of these drugs has been a 'gold standard' for several years. However, there is an emerging knowledge of the biology and sensitivity to treatment for different histological subtypes. New drugs such as gemcitabine, taxanes and trabectedin have been explored in several studies, showing promising results. Even if most studies have encompassed many different subtypes and were limited in size, knowledge related to specific treatment for different subtypes is emerging. Examples are trabectedin in liposacoma and leiomyosarcoma, and taxanes in angiosarcoma.}}, author = {{Eriksson, Mikael}}, booktitle = {{Educational Book of the 35th ESMO Congress Milan, Italy, 8-12 October 2010}}, issn = {{1569-8041}}, language = {{eng}}, pages = {{270--276}}, series = {{Annals of Oncology}}, title = {{Histology-driven chemotherapy of soft-tissue sarcoma.}}, url = {{http://dx.doi.org/10.1093/annonc/mdq285}}, doi = {{10.1093/annonc/mdq285}}, volume = {{21}}, year = {{2010}}, }